Skip to main content


Table 1 Clinical and pathologic features, diagnosis, treatment, and outcome of peripheral neuroectodermal tumors of the cervix

From: Ewing’s sarcoma of the cervix, a diagnostic dilemma: a case report and review of the literature

  Author Age Symptoms Diagnosis Stage Surgery Chemotherapy/intent of chemotherapy Radiation therapy Outcome
1 Russin et al. 1987 [21] 60 Vaginal bleeding Path/IHC IB TAH + BSO + LND VAC for 6 weeks/adjuvant Yes Alive at 16 months, NED
2 Sato et al. 1996 [22] 44 Irregular vaginal bleeding Path/IHC IB2 TAH + BSO + LND, second look after 6 months Cisplatin, VP16, cyclophosphamide (Cytoxan), doxorubicin (Adriamycin)/adjuvant No Alive 6 months, NED
3 Horn et al. 1997 [2] 26 Suspect cervical smear Path/IHC IB1 TAH + BSO + LND No adjuvant chemotherapy; had lung metastases 3 years after diagnosis, received 5FU and cisplatin/palliative RT to metastases Died 4.2 years after diagnosis
4 Cenacchi et al. 1998 [15] 36 Irregular vaginal bleeding Path/IHC/RT-PCR IB2 TAH without BSO No No Alive 18 months, NED
5 Pauwels et al. 2000 [14] 45 Irregular vaginal bleeding Path/IHC/FISH IB2 TAH No Pelvic RT Alive 42 months, NED
6 Tsao et al. 2001 [3] 24 Vaginal bleeding, urinary frequency Path/IHC   TAH + transposition of ovaries + LNS Two cycles, VAC alternating with IE, neoadjuvant and adjuvant Yes Alive 24 moths, NED
7 Malpica and Moran 2002 [6] 35 Vaginal bleeding Path/IHC IB1 TAH + BSO + LND Adjuvant chemotherapy/regimen not reported No Alive 5 months, NED
8 Malpica and Moran 2002 [6] 51 Vaginal bleeding Path/IHC IB2 TAH + BSO + LND Adjuvant chemotherapy/regimen not reported No Alive 18 months, NED
9 Snijders-Keilholz and Ewing 2005 [17] 21 Intermenstrual bleeding Path/IHC IB2 TAH without adnexectomy Six courses of DIME/neoadjuvant; five courses of VIA/adjuvant No Alive 27 months, NED
10 Goda et al. 2007 [19] 19 Vaginal bleeding, discharge    No Induction VAC, planned for further consolidation after RT Yes Alive, on treatment when reported
11 Farzaneh et al. 2011 [23] 43 Purulent vaginal discharge Path/IHC IB2 TAH + BSO + LNS 12 weeks of VAC alternating with IE/neoadjuvant No Alive 4 years, NED
12 weeks of VAC alternating with IE/adjuvant
12 Benbrahim et al. 2012 [9] 25 Irregular vaginal bleeding Path/IHC IIb Coniztion with brachytherapy Four cycles of Adriamycin and Cytoxan/neoadjuvant Yes Alive 8 years, NED
13 Arora et al. 2012 [4] 23 Irregular bleeding, dysuria Path/IHC   TAH + BSO + LND One cycle of CAV, followed by two cycles of cis/VP16/neoadjuvant Yes Alive 4 years, NED
14 Masoura et al. 2012 [16] 23 Irregular bleeding, abdominal pain Path/IHC/RT-PCR IV TAH + BSO Cisplatin once/adjuvant No. Died, 12 days
15 Li et al. 2013 [5] 27 Contact bleeding, abdominal pain Path/IHC IIIB Unresectable VAC alternating with IE/definitive chemotherapy Yes Alive at 6 months, NED
16 Khosla et al. 2014 [24] 28 10 weeks pregnant with vaginal bleeding and pelvic pain Path/IHC IB2 Termination of pregnancy, TAH + BSO + LNS Adriamycin, IE, for total of 6 weeks/adjuvant No Alive 33 months, NED
17 Xiao et al. 2014 [18] 52 Vaginal bleeding, uterine enlargement Path/IHC IIA TAH + BSO + LND Two courses of PVB   Pelvic recurrence 6 months, DOD 9 months
18 Xiao et al. 2014 [18] 59 Cervix prolapse, vaginal bleeding Path/IHC IVB TAH + BSO + LND None   DOD
19 Present case 49 Vaginal bleeding, lower abdominal pain Path/IHC/FISH IIB TAH + BSO Cisplatin/Etoposide with RT due to diagnosis of small cell VAC alternating with IE/adjuvant Yes Died, 10 months
  1. 5FU 5-fluorouracil, BSO bilateral salpingo oophorectomy, DIME Doxorubicin, Ifosfamide, Mesna, Etoposide, DOD died of disease, FISH fluorescent in situ hybridization, IE Ifosfamide, Etoposide, IHC immunohistochemical studies, LND/LNS pelvic lymphadenectomy/lymph node sampling, LSO left-sided oophorectomy, NED no evidence of disease, PVB Cisplatin, Vincristine, Bleomycin, RT radiation therapy, RT-PCR reverse transcriptase polymerase chain reaction, TAH total abdominal hysterectomy, VAC Vincristine, Adriamycin, Cyclophosphamide, VIA Vincristine, Ifosfamide, Dactinomycin, VP16 Etoposide